Healthcare Industry News: gut microbiome
News Release - September 26, 2017
Eligo Bioscience Secures $20 Million Series A from Khosla Ventures and Seventure to Bring Precision Medicine to the MicrobiomeFrench biotech company has produced the first biotherapeutic nanobots to engineer the microbiome.
PARIS, Sept. 26, 2017 -- (Healthcare Sales & Marketing Network) -- Eligo Bioscience, the French microbiome company developing drugs to prevent and treat bacteria-associated diseases, has secured a $20 million Series A round of financing from Khosla Ventures and Seventure Partners, including a $2 million award from the Worldwide Innovation Challenge. This comes just months after Eligo was selected as one of the 30 Most Innovative Companies in 2017 by the World Economic Forum. This funding will enable Eligo to strengthen its biotherapeutic platform, begin clinical trials for its lead indication and extensively grow its international team of scientists, engineers, and executives.
A growing body of research shows that the microbiome, made up of the ten trillion bacteria residing within and on the human body, sits "at the interface of health and disease." While some of these bacteria are critical to overall health, others are strongly associated with serious conditions such as as inflammatory bowel disease (IBD), colorectal cancer, type 2 diabetes and neurodegenerative diseases.
Although microbiome health will be a future cornerstone of personalized and precision medicine, there are currently no ways to selectively intervene on the microbiome. Prebiotics and probiotics, designed to strengthen or restore a healthy microbiome and encourage the growth of "good" bacteria, have variable impact. Antibiotics, on the other hand, kill bacteria too indiscriminately, often affecting both the disease-causing bacteria and the healthy microflora. Antibiotics also often have serious short-term side-effects, and, in the long term, they are directly contributing to the rise of antibiotic-resistant infections and the emergence of superbugs. The World Health Organization predicts that infections from antibiotic-resistant bacteria will be a leading cause of mortality by 2050.
To confront these challenges, Eligo is developing the world's first programmable biotherapeutics platform, specifically designed to treat bacteria-related diseases at their source and improve overall microbiome health. This new generation of drugs, eligobiotics, are essentially biological nanobots, built of DNA and protein, that deliver a customized therapeutic payload to specific types of bacteria. Upon finding their target, these nanobots can either kill the bacteria or transiently turn them into drug producers depending on the payload they carry.
"Antibiotics are weapons of mass destruction: extremely powerful but imprecise. With eligobiotics, we can precisely intervene on the microbiome – targeting specific bacteria for interventions of our choice. By engineering the microbiome itself with sniper-like precision, we can address the cause, not just the symptoms, of bacteria-associated diseases," said Eligo CEO Dr. Xavier Duportet.
The first application of the eligobiotics platform is targeting specific diseases by delivering a CRISPR-Cas payload into gut microbiome to selectively kill pathogenic bacteria. Once inside the bacteria, the CRISPR system first scans the bacterial DNA for the culprit gene. If the sequence is detected, the CRISPR system cuts the DNA beyond repair, killing the bacteria almost instantly. This selective process ensures the removal of the pathogenic bacteria while leaving the rest of the microbiome intact, allowing the rest of the flora to reestablish a healthy balance. But CRISPR is the just the first part of the story. Indeed, the modularity of Eligo's platform also enables the delivery of other payloads into the microbiome to modulate immune responses, drug metabolism or create transient drug production directly from within the gut, opening a wide range of applications.
"Xavier and the Eligo team have managed to use the tools of synthetic biology to create an elegant solution to an unbelievably complex problem: how to target, with extreme precision, the root causes of microbiome-associated diseases," said Khosla Ventures partner Samir Kaul. "We're proud to lead this investment in Eligo Bioscience, a shining example of an innovative startup using the tools of synthetic biology to tackle the world's most pressing problems."
"Launching our microbiome fund has quickly given us an eagle's eye view into this space and into the companies at its core," said Seventure Partners CEO Isabelle de Cremoux. "The Eligo team stands out as a leader and pioneer in this space, and we are proud to support them at this exciting point in their timeline."
About Eligo Bioscience
Eligo Bioscience is a preclinical-stage synthetic biology company developing a biotherapeutics platform to bring precision medicine to the microbiome. The company produces eligobiotics, biological nanobots built of DNA and protein, that deliver a customized therapeutic payload to specific types of bacteria. To date, Eligo has raised $24 million and was selected as one of the 30 Most Innovative Companies in 2017 by the World Economic Forum. Currently headquartered in Paris, France, Eligo was founded in 2014 by Dr. Xavier Duportet, Dr. David Bikard and Associate Professors Timothy Lu from MIT and Luciano Marraffini from Rockefeller University.
For more details: www.eligo-bioscience.com / Twitter @eligobio
About Health For Life Capital™ and Seventure partners
Seventure Partners launched Health for Life Capital™, the first venture capital fund focused mainly on investments in the microbiome, food and nutrition space. Europe is the primary focus of the fund, but it also invests in North America, Israel and Asia. The €160m fund attracted strategic investments from prestigious organizations including Danone, Novartis, Tereos, Tornier, Lesaffre and Bel, as well as financial institutions and entrepreneurs. Health for Life Capital™ is managed by Seventure's Life sciences team.
With over €660m in assets under management as of the end of 2016, Seventure Partners is a leading venture capital firm in Europe. Investments can range between €500k and €10m per round, or up to €20m per company, from early to late stage.
For more details:www.seventure.com / Twitter @SeventureP
About Khosla Ventures
Khosla Ventures is a venture capital firm that provides venture assistance and strategic advice to entrepreneurs working on breakthrough technologies. The firm was founded in 2004 by Vinod Khosla, co-founder of Sun Microsystems, and focuses on transformative technology in consumer, enterprise, education, financial services, health, big data, agriculture/food, sustainable energy and robotics. Khosla Ventures is headquartered in Menlo Park, California. For more information about the firm's activities, please visit https://www.khoslaventures.com.
Source: Eligo Bioscience
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.